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ABSTRACT
Objective: This study aimed to monitor the side effects of carbamazepine, phenytoin, and valproic acid, and combinations of these drugs in adult 
patients with epilepsy, to raise awareness of the importance of drug side effect monitoring in hospitals.
Methods: In this prospective study, descriptive data were collected from patients who met the inclusion criteria of complete samples. Primary data 
were obtained using questionnaires, secondary data were collected from medical records, and analyses were performed using the Naranjo algorithm.
Results: Among the 54 included patients, 38 (70.37%) of them experienced drug side effects, and the most frequently observed side effect occurred 
in 48.15% of study subjects.
Conclusion: No correlation was identified between side effects and age (p=0.903) or gender (p=1.000).
Keywords: Carbamazepine, Naranjo algorithm, Phenytoin, Side effects, Valproic acid.
INTRODUCTION
It is estimated that 2.4 million people are diagnosed with epilepsy 
annually, and 70% of those receiving proper therapy is free of side 
effects. In developing countries, however, 80–90% of epileptic 
patients do not receive proper treatment [1]. In Indonesia, 5–12 per 
1000 people are diagnosed with epilepsy each year [2], and these 
patients are commonly treated with anticonvulsants. Special attention 
must be given when administering these drugs due to high rates of 
therapeutic failure, and because they often have narrow therapeutic 
indexes (TI) [3].
Anticonvulsants with narrow TI include carbamazepine, phenytoin, 
and valproic acid [4]. In all of these drugs, the difference between the 
toxic and the therapeutic dose range is small, which often leads to 
problems when dosages are changed slightly or in interactions with 
other drugs. According to a study by the University of Oslo and the 
Norwegian Pharmacy Association, 80% of 827 patients receiving drugs 
with narrow TI experienced drug-related problems, and only 67% did 
not experience any problems related to drugs [5].
Problems related to drugs include poor therapy efficacy, side effects, 
and high treatment costs [6-9]. Drug side effects are defined as 
harmful or unwanted responses at doses that are used for prevention, 
diagnosis, or therapy [10]. Side effects may also be related to individual 
susceptibilities and can, therefore, be managed by dosage adjustment or 
discontinuation of the treatment [11]. Accordingly, dose management is 
performed with careful monitoring of clinical side effects.
Side effects in patients consuming anticonvulsants with narrow TI may 
be influenced by gender and age. Moreover, based on a previous study, 
25–30% of pregnant women experienced increased frequencies of 
seizures. Women also suffer from catamenial epilepsy, which increases 
the frequency of seizures during menstruation or ovulation [12]. These 
two conditions necessitate higher doses, which lead to increased serum 
concentrations of anticonvulsants, and increase the risk of side effects. 
Finally, the effects of age on rates of drug side effects have been related 
to changes in pharmacokinetics in elderly patients [13].
Indonesian Ministry of Health Regulation No. 72 2016 suggests that 
monitoring of drug side effects should be a pharmaceutical standard 
of care in hospitals. These investigators monitored the side effects of 
carbamazepine, phenytoin, and valproic acid, which are anticonvulsant 
drugs with narrow TI and have known side effects. Since monitoring of 
drug side effects is critical to the prevention of serious side effects of 
known or unknown causes, we collected qualitative and quantitative 
data from a series of patients and monitored drug side effects using the 
Naranjo algorithm [10].
This study was conducted at Fatmawati Central General Hospital, which 
is a Type A hospital with the highest referral for patients. Due to the 
extensive specialist and subspecialist services at this hospital, epilepsy 
is the fourth most frequent nerve disease treated in the outpatient 
department. The purpose of this study was to raise awareness of the 
importance of drug side effect monitoring in hospitals.
METHODS
Sampling
Data were collected from outpatients consuming carbamazepine, 
phenytoin, or valproic acid, or combinations of these drugs. Patients 
from the Fatmawati Central General Hospital were included according 
to the inclusion and exclusion criteria during the period from March to 
May 2017.
Validity and reliability tests of the questionnaire
Primary data were collected from the included patients using a 
questionnaire, which was subjected to validity and reliability testing. 
These tests were used to assess whether the questionnaire was 
sufficient for the study hypothesis and to assess its reliability according 
to within-subject consistency.
Data processing
Data from interviews and observations were checked for completeness, 
relevance of answers to questions, and consistency between questions. 
After editing all questionnaires, the data were coded by converting 
sentences and characters into numeric data and were then analyzed 
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using SPSS version 23. After analyzes of all data, code errors, omissions, 
and other inconsistencies were screened, and the data were cleaned by 
eliminating instances of missing variables and inconsistent data [14].
Data analysis
Data were analyzed using univariate and bivariate regression models, 
which returned frequencies and percentage rates for each variable [14]. 
Patient characteristics included age, gender, and data for anticonvulsant 
use, such as daily dosages and drug side effect classifications according 
to the Naranjo algorithm.
The Naranjo algorithm was used to qualitatively and quantitatively 
identify adverse drug reactions (ADR) following administration of 
the anticonvulsants carbamazepine, phenytoin, and valproic acid. The 
Naranjo algorithm is comprised of 10 questions, and the probability 
of side effects was determined based on total scores for all questions. 
These scores were classified into the categories of highly probable, 
probable, possible, and doubtful (Table 1) [10].
Characteristics or distributions of variables were used in bivariate 
analyzes of relationships between the side effects of carbamazepine, 
phenytoin, or valproic acid, and age and gender. Significant relationships 
were identified using Chi-square test [14].
RESULTS
Study subjects
During the period from March to May 2017, a total of 76 patients 
were administered carbamazepine, phenytoin, valproic acid, or a 
combination of those drugs in the Outpatient Department of Fatmawati 
Central General Hospital. 54 of these were included as study subjects, 
whereas 20 patients refused to participate, and 1 patient was excluded 
due to a diagnosis of cerebral palsy and tremors. Another patient was 
excluded because carbamazepine, phenytoin, or valproic acid therapy 
was stopped within 1 month. Patient characteristics are listed in Table 2.
Side effects
Observed side effects were divided into categories of probable and possible, 
with 26 (48.15%) and 12 patients (22.22%), respectively. Whereas 38 
subjects (70.37%) experienced side effects, 16 (29.63%) did not (Table 3).
The results of this study showed that the present anticonvulsants were 
associated with different dominant side effects (Table 4).
DISCUSSION
Patient characteristics
Among the present 18–65-year-old patients, 51 (94.44%) were below 
the age of 60 and received carbamazepine, phenytoin, valproic acid, or 
a combination of these drugs. In a previous study, seizures and epilepsy 
were more frequently seen in patients over 60, and we included 
3 (5.56%) elderly patients in this study. Seizures can be triggered by 
acute disease or can occur spontaneously. Epilepsy is also more common 
among the elderly, as indicated previously by greater numbers of first 
seizures in patients of 65 or above (136 subjects) than in those between 
the ages of 40 and 59 (50–60) [13]. Elderly subjects are comparatively 
few in our study and are not representative of the whole population, 
likely reflecting the short study period.
Numbers of female and male epileptic patients receiving carbamazepine, 
phenytoin, valproic acid, or a combination of these drugs were similar 






Table 2: Characteristics of epilepsy patients
Category Number of patients
n=54 (%)
Age
Non-elderly (18–60 years) 51 (94.44)





Mental retardation 2 (3.7)
Tuberculous spondylitis 1 (1.85)
Hypertension 2 (3.7)
Post-stroke 1 (1.85)
Usage of single anticonvulsant 31 (57.41)
Carbamazepine 7 (14.81)
Phenytoin 12 (22.22)
Valproic acid 12 (22.22)
Combination 23 (42.59)
Carbamazepine and valproic acid 9 (14.81)
Phenytoin and valproic acid 14 (25.93)
Daily dosage
Single carbamazepine
2×200 mg 2 (3.70)
3×200 mg 5 (9.26)
Single phenytoin
2×100 mg 2 (3.70)
3×100 mg 8 (14.81)
4×100 mg 2 (3.70)
Single valproic acid
1×250 mg 1 (1.85)
2×250 mg 3 (5.56)
1×500 mg 3 (5.56)
2×500 mg 1 (1.85)
3×500 mg 1 (1.85)
1×750 mg 1 (1.85)
1×1000 mg 1 (1.85)
1×2000 mg 1 (1.85)
Combination of carbamazepine and valproic acid
Carbamazepine
2×200 mg 1 (1.85)
3×200 mg 4 (7.41)
4×200 mg 1 (1.85)
5×200 mg 1 (1.85)
1×300 mg 1 (1.85)
2×300 mg 1 (1.85)
Valproic acid
1×250 mg 1 (1.85)
1×500 mg 3 (5.56)
1×750 mg 1 (1.85)
1×1000 mg 1 (1.85)
2×500 mg 1 (1.85)
2×1000 mg 1 (1.85)
3×250 mg 1 (1.85)
Combination of phenytoin and valproic acid
Phenytoin
3×100 mg 11 (20.37)
4×100 mg 3 (5.56)
Valproic acid
1×250 mg 2 (3.70)
1×500 mg 2 (3.70)
1×750 mg 1 (1.85)
1×1500 mg 1 (1.85)
2×250 mg 3 (5.56)
2×500 mg 2 (3.70)
3×500 mg 2 (3.70)
4×500 mg 1 (1.85)
in our hospital, with 26 females and 28 male subjects. The percentage 
of female patients receiving anticonvulsants was 48.15%, and that of 
male patients were 51.85%. In a similar study published by Universitas 
Malta, the incidence of epilepsy in males was only slightly higher than 
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in females [15]. A study conducted by the Pharmacology Department 
of Universitas Aarhus also demonstrated no significant difference 
between numbers of male and female epileptic patients. Nonetheless, 
symptomatic epilepsy is more common in males, and cryptogenic 
epilepsy is more common in females [16].
Whereas epilepsy was the primary diagnosis in all of our subjects, some 
had other conditions, such as mental retardation (3.7%), tuberculous 
spondylitis (1.85%), hypertension (3.7%), and stroke (1.85%). This 
rate of mental retardation among epilepsy patients is low according 
to a study of 456,000 epileptic patients by the Joint Epilepsy Council 
of Great Britain and Ireland, who showed that 1 in 5 epilepsy patients 
had mental retardation [17]. Chronic hypertension has also been 
associated with the risk of epilepsy and is a well-described predictor 
of cerebrovascular diseases such as stroke. In elderly stroke patients, 
seizures are the most commonly seen neurologic symptom and usually 
occur within a few years after a stroke in around 10% of patients [18].
In this study, 57.41% of subjects received carbamazepine, phenytoin, or 
valproic acid only, and 42.59% received carbamazepine or phenytoin in 
combination with valproic acid. Whereas narrow TI is associated with 
single and combination anticonvulsant therapy, neurology related side 
effects such as dizziness, sleepiness, and fatigue are reportedly more 
common with combined anticonvulsant therapy. These investigators 
also reported that only a few patients did not experience seizures 
during combined anticonvulsant therapy [19].
The present dosage regimens (Table 2) were most commonly single or 
combination therapies of carbamazepine, phenytoin, and valproic acid 
at 3×200 (16.67%), 3×100 (35.18%), and 1×500 mg/day (14.82%), 
respectively.
Side effects
The most frequently observed side effect of carbamazepine was 
sleepiness and was documented in 6 subjects (15.79%). Carbamazepine 
can decrease the duration of rapid eye movement (REM) and non-REM 
3 sleep stages, thereby reducing sleep quality [20].
In contrast, phenytoin caused fatigue in 5 of our subjects (13.16%) and 531 
out of 12,077 people in a study by the Food and Drug Administration [21].
In the present and previous studies, valproic acid most commonly 
causes side effects of tremor, which was seen in 6 patients (15.79%), 
and is a reported effect of long-term use of valproic acid. Since valproic 
acid increases glutamate metabolism, it increases circulating ammonia 
concentrations. Under normal conditions, serum ammonia is present 
at 10–40 μmol/L and causes tremors at 120 μmol/L [22]. According to 
a study by the WHO, tremor is the most common side effect of valproic 
acid [1]. Sleepiness is the most common side effect of combination 
therapy with carbamazepine and valproic acid and was observed 
in 4 of our patients (10.53%). Accordingly, serum carbamazepine 
concentrations were previously associated with sleepiness [12]. In 
patients receiving the combination of phenytoin and valproic acid, 
the most commonly observed side effect was dizziness (7 patients; 
18.42%). Accordingly, dizziness was previously associated with serum 
phenytoin concentrations of 20 mg/mL [23].
Relationships of drug side effects with gender and age
Among the 26 female subjects, 19 (73.1%) suffered side effects 
of anticonvulsants. Similarly side effects occurred in 19 out of the 
28 (67.9%) male subjects, and no significant sex-related differences 
were identified in Chi-square test (p=0.903). The Chi-square test 
resulted in a score of <5; therefore, the p score in the continuity 
correlation was used [24]. However, female subjects with epilepsy 
experience various physiological changes that may affect the types of 
side effects experienced. In particular, increased ratios of estrogen to 
progesterone during menstruation are a likely contributor to clinical 
outcomes, as estrogen and progesterone have mild epileptogenic 
and antiepileptogenic properties, respectively. This was previously 
indicated by increased frequencies of seizures during menstruation 
in female patients with partial epilepsy, and the resultant necessity 
of higher dosages leading to increased susceptibility to side 
effects [2]. Comparatively, low estrogen hormone levels in males 
should be accompanied by lower [25] and less variable seizure rates, 
precluding changes in doses and fewer side effects.
In the present study, side effects were observed in 70.6% of non-elderly 
subjects and 2 out of 3 elderly subjects (66.7%), but no significant 
age-related differences were identified in Chi-square test (p=1.000). 
The management of elderly epileptic patients, nonetheless, requires 
caution due to reduced organ function and basal metabolic rates [2]. 
Anticonvulsant pharmacokinetics have also been shown to change in 
the elderly [13], reflecting reduced liver mass and hepatic metabolism, 
which is required for clearance of some anticonvulsants. Reduced 
kidney function also limits creatinine clearance of anticonvulsants, 
and carbamazepine creatinine clearance was reportedly 30–40% less 
in elderly patients [13]. Finally, albumin concentrations are reduced 
in the elderly, and because carbamazepine, phenytoin, and valproic 
acid have high protein-bound percentages of 40–90%, 90%, and 90–
95%, respectively, albumin concentrations of <3.5–4.5 g/dL may limit 
clearance of these drugs in the elderly. These three pharmacokinetic 
changes all contribute to increases in serum concentrations of drugs 
in the elderly, which leads to higher susceptibility to side effects [13].
CONCLUSION
Based on the results of this study, we conclude that patients receiving 
anticonvulsant drugs are mostly non-elderly (94.4%) and are most 
commonly treated with single anticonvulsant drugs (57.41%). Whereas 
Table 3: Categories of side effects
Category Total n=54 (%)
Naranjo’s side effect category




Did not experience any side effects 16 (29.63)
Table 4: Side effects experienced by patients
Category Total n=38 (%)
Carbamazepine
Diplopia 0 (0)









Gastrointestinal problems 1 (2.63)
Disturbances in balance 3 (7.89)
Tremor 6 (15.79)
Combination of carbamazepine and valproic acid
Disturbances in balance 3 (7.89)
Sleepiness 4 (10.53)
Dizziness 3 (7.89)
Gastrointestinal problems 2 (5.26)
Tremor 3 (7.89)
Combination of phenytoin and valproic acid
Blurred vision 4 (10.53)
Dizziness 7 (18.42)
Fatigue 3 (7.89)
Gastrointestinal problems 4 (10.53)
Disturbances in balance 1 (2.63)
Tremor 3 (7.89)
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side effects were categorized as probable with a percentage of 48.15% 
and possible with a percentage of 22.22%, the most commonly observed 
side effect was dizziness (18.42%) due to combination treatment 
with phenytoin and valproic acid. Finally, no significant relationships 
between side effects and age and gender were identified.
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